Platelet Amyloid Precursor Protein Abnormalities in Mild Cognitive Impairment Predict Conversion to Dementia of Alzheimer Type

Borroni, Barbara; Colciaghi, Francesca; Caltagirone, Carlo; Rozzini, Luca; Broglio, Laura; Cattabeni, Flaminio; Luca, Monica Di; Padovani, Alessandro

doi:10.1001/archneur.60.12.1740

Cited by 61 publications

(42 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data obtained showed that there was no association between amyloid precursor protein ratios and any specific ApoE allele (Sanchez-Gonzalez et al, 2006). In concordance to previous studies, we observed a significant decreased amyloid precursor protein ratio on AD subjects as compared to that of control subjects (Utermann, 1987;Borroni et al, 2003). This means that an increased degradation of this precursor protein is being performed in peripheral tissues.…”

Section: Amyloid Precursor Proteinsupporting

confidence: 90%

Role of Mitochondria in Alzheimer ́s Disease

Ortiz¹,

Pacheco-Moisés²,

García-Trejo³

et al. 2011

Alzheimer's Disease Pathogenesis-Core Concepts, Shifting Paradigms and Therapeutic Targets

View full text Add to dashboard Cite

Section: Amyloid Precursor Proteinsupporting

confidence: 90%

Role of Mitochondria in Alzheimer ́s Disease

Ortiz¹,

Pacheco-Moisés²,

García-Trejo³

et al. 2011

Alzheimer's Disease Pathogenesis-Core Concepts, Shifting Paradigms and Therapeutic Targets

View full text Add to dashboard Cite

“…Among those, platelet forms of amyloid precursor protein have been proposed. At two-year follow-up MCI subjects who converted to AD showed a significant decrease of baseline platelet APP forms ratio compared to nonconverters, with a sensitivity of 83% and a specificity of 71% [20].…”

Section: Predictors Of Progression Of MCI To Dementiamentioning

confidence: 93%

Mild Cognitive Impairment: A Systematic Review

Mariani

Monastero

Mecocci

2007

JAD

213

182

View full text Add to dashboard Cite

Abstract. MCI is a nosological entity proposed as an intermediate state between normal aging and dementia. The syndrome can be divided into two broad subtypes: amnestic MCI (aMCI) characterized by reduced memory, and non-amnestic MCI (naMCI) in which other cognitive functions rather than memory are mostly impaired. aMCI seems to represent an early stage of AD, while the outcomes of the naMCI subtypes appear more heterogeneous -including vascular dementia, frontotemporal dementia or dementia with Lewy bodies-but this aspect is still under debate. MCI in fact represents a condition with multiple sources of heterogeneity, including clinical presentation, etiology, and prognosis. To improve classification and prognosis, there is a need for more sensitive instruments specifically developed for MCI as well as for more reliable methods to determine its progression or improvement. Current clinical criteria for MCI should be updated to include restriction in complex ADL; also the diagnostic and prognostic role of behavioral symptoms and motor dysfunctions should be better defined. A multidisciplinary diagnostic approach including biological and neuroimaging techniques may probably represent the best option to predict the conversion from MCI to dementia. In this review we discuss the most recent aspects related to the epidemiological, clinical, neuropathological, neuroimaging, biochemical and therapeutic aspects of MCI, with specific attention to possible markers of conversion to dementia.

show abstract

“…To this aim, subjects with MCI were enrolled, and were followed up periodically for 2 years, and the progression to dementia was evaluated (Borroni et al, 2003). Interestingly, MCI individuals who progressed to AD showed a significant decrease of baseline platelet APP forms ratio values (mean±SD, 0.36±0.28) when compared with stable MCI subjects (0.73±0.32, P<.01) and patients who developed other types of dementia (0.83±0.27, P=.03) (see Figure 2 and Figure 3).…”

Section: Platelet Amyloid Precursor Protein As a Diagnostic Marker Inmentioning

confidence: 99%

“…By fixing a cutoff score of 0.6, the sensitivity of APP ratio marker in detecting preclinical AD was 83%, while the specificity was 71%. This study suggested that alteration of platelet APP forms is an early event in AD, antedating clinical symptoms up to at least two years, and 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 10 that the measurement of APP ratio may be useful for the identification of preclinical AD in subjects with MCI (Borroni et al, 2003). This is in line with the general knowledge that biological changes antedate the onset of symptoms in neurodegenerative disorders.…”

Section: Platelet Amyloid Precursor Protein As a Diagnostic Marker Inmentioning

confidence: 99%

Blood cell markers in Alzheimer Disease: Amyloid Precursor Protein form ratio in platelets

Borroni

Agosti²,

Marcello³

et al. 2010

Experimental Gerontology

Self Cite

View full text Add to dashboard Cite

A correct clinical diagnosis in the early stage of Alzheimer disease (AD) is mandatory given the current available treatment with acetylcholine esterase inhibitors. Moreover, a early to preclinical diagnosis would allow to identify patients eligible for future diseasemodifying therapies.In the last ten years, we have focused our attention on peripheral markers, evaluating the role of platelet Amyloid Precursor Protein (APP) forms as a reliable tool for AD diagnosis since preclinical stages. APP is the key player in AD pathogenesis, and platelets contain all the enzymatic machinery to its processing, thus being the ideal candidate where to study AD pathogenetic mechanisms.In this review, we summarise the published data regarding the usefulness of platelet APP form ratio in the diagnosis of early AD. Approaches combining APP form ratio along with neuroimaging markers show the promise to accurately identify AD, even in the pre-symptomatic stage.

show abstract

Platelet Amyloid Precursor Protein Abnormalities in Mild Cognitive Impairment Predict Conversion to Dementia of Alzheimer Type

Abstract: Mild cognitive impairment is a major risk factor for DAT, and Alzheimer disease-related pathological changes can be identified in patients converting to DAT within a 2-year follow-up.

Cited by 61 publications

References 34 publications

Role of Mitochondria in Alzheimer ́s Disease

Role of Mitochondria in Alzheimer ́s Disease

Mild Cognitive Impairment: A Systematic Review

Blood cell markers in Alzheimer Disease: Amyloid Precursor Protein form ratio in platelets

Contact Info

Product

Resources

About